Wall Street analyst estimates for Oramed Pharmaceuticals Inc. (ORMP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.75 |
Valuation Ratios
| P/E Ratio | 1.09 |
| Price / Book | 0.60 |
| EV / EBITDA | 1.26 |
| Dividend Yield | 5.41% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $641000 | $2.5M | $2.4M | $2.7M | $2.7M | $2.7M | $2.7M | $1.3M | 0 | $2.0M |
| Cost of Revenue | $490000 | $187000 | $86000 | $90000 | 0 | 0 | 0 | 0 | 0 | $2.0M |
| Gross Profit | $151000 | $2.3M | $2.4M | $2.6M | $2.7M | $2.7M | $2.7M | $1.3M | 0 | $13000 |
| Research & Development | $7.7M | $10.3M | $12.0M | $13.5M | $10.2M | $21.0M | $27.6M | $9.0M | $6.3M | $6.4M |
| Selling, General & Admin | $2.5M | $2.8M | $4.1M | $3.7M | $4.2M | $5.9M | $15.7M | $8.1M | $6.5M | $8.7M |
| Operating Expenses | $10.2M | $13.0M | $16.1M | $17.2M | $14.5M | $26.9M | $43.3M | $17.1M | $12.8M | $15.1M |
| Operating Income | -$10.0M | -$10.8M | -$13.5M | -$14.6M | -$11.8M | -$24.2M | -$40.6M | -$15.8M | -$12.8M | -$15.1M |
| EBITDA | -$10.0M | -$10.8M | -$13.5M | -$14.2M | -$11.8M | -$24.1M | -$37.0M | $7.3M | -$14.9M | $75.4M |
| Interest Expense | $11000 | $6000 | $6000 | 0 | 0 | 0 | 0 | $3.6M | $853000 | 0 |
| Pre-tax Income | -$9.6M | -$10.1M | -$12.7M | -$14.1M | -$11.5M | -$23.0M | -$37.7M | $5.1M | -$15.9M | $75.3M |
| Income Tax | $1.3M | $400000 | -$800000 | $300000 | 0 | 0 | $100000 | 0 | $3.2M | $11.3M |
| Net Income | -$11.0M | -$10.5M | -$12.7M | -$14.4M | -$11.5M | -$22.2M | -$37.8M | $5.5M | -$19.1M | $64.0M |
| EPS | $-0.87 | $-0.79 | $-0.86 | $-0.82 | $-0.56 | $-0.78 | $-0.97 | $0.14 | $-0.48 | $1.53 |
| EPS (Diluted) | $-0.87 | $-0.79 | $-0.86 | $-0.82 | $-0.56 | $-0.78 | $-0.97 | $0.14 | $-0.48 | $1.50 |
| Shares Outstanding (Diluted) | $12.6M | $13.3M | $14.9M | $17.5M | $20.5M | $28.5M | $39.0M | $40.6M | $40.9M | $42.4M |
Price
| Price | $4.62 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLNN · CNTB · CNTX · COYA · IFRX · IMA · KLRS
Explore sector: Healthcare · Biotechnology
More sections of ORMP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks